Antibody-drug combo with radiation for HER2+ UTUC after surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have upper tract urothelial cancer (cancer in the kidney or ureter) that has high-risk features like being deep, high-grade, or in lymph nodes.
- Your cancer cells tested positive for HER2 (score 2+ or 3+).
- You have already had surgery to remove all visible cancer, and imaging shows no spread at least 4 weeks after surgery.
- You cannot receive cisplatin chemotherapy (e.g., due to kidney problems).
- You are in good overall health (able to perform daily activities) and your blood counts and organ function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy (disitamab vedotin, also called RC48) given directly into the bladder after surgery for HER2-positive upper tract urothelial cancer. The goal is to see if it helps prevent the cancer from coming back.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This trial tests a combination of two drugs and radiation therapy given before surgery for high-risk upper tract urothelial cancer. The goal is to see if this approach can improve outcomes for patients who are eligible for surgery.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
Hear when a new Upper Urinary Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.